Eco-design and medicine: Opportunities to implement eco-design in the pharmaceutical R&D process
Article dans une revue avec comité de lecture
Date
2022-06-19Journal
Journal of Cleaner ProductionRésumé
The pharmaceutical sector has the societal duty to make medical healthcare products both available and affordable. But like any human activity, it is not neutral in terms of environmental impact. Therefore, and like any industry, the pharmaceutical sector needs to consider the environmental aspects into its product design and activities in order to reach a sustainable production and consumption patterns, as defined by the Sustainable Development Goal (SDG) 12 of the United Nations. With a holistic perspective, the eco-design concept is an approach that aims to integrate environmental aspects into product design. To contribute to the SDGs, the pharmaceutical industry needs to consider the environmental impacts of its products. Usually, experts within Research & Development (R&D) do not have the proper level of knowledge to integrate the environmental aspects, in a Lifecycle perspective, into their decision making. Even so, those parameters are not yet part of the New Product Development (NPD) process of the medicine product. With those elements in mind, the aim of this paper is to understand which phases of the pharmaceutical R&D process represent an opportunity to eco-design such products.
We proposed two qualitative experimentations with, first interviewing ten practitioners of R&D; and second, with an assessment of the medicine NPD process and related deliverables, based on LCA results. The use of such results to investigate potential key contributors during NPD stages does not seem to be explored yet, especially for the pharmaceutical sector.
Results show that eco-design approaches can be performed all along the development of a pharmaceutical product. Main eco-design levers appear in parallel to the clinical phases 2a and 2b, in other words, when the tests on the final marketed form are initiated.
Fichier(s) constituant cette publication
Cette publication figure dans le(s) laboratoire(s) suivant(s)
Documents liés
Visualiser des documents liés par titre, auteur, créateur et sujet.
-
A Novel Multi-Criteria Risk Matrix to Assist in the Strategy Formulation Process: The Case of SMEs Article dans une revue avec comité de lectureVASNIER, Jean-Marc; MESSAADIA, Mourad; AOUSSAT, Améziane; MARANZANA, Nicolas (World Scientific Pub Co Pte Lt, 2021)Small and medium-sized enterprises (SMEs) are the spine of the European economy and play a key role in adding value in all sectors of the economy. However, due to a lack of methodology and time, SME entrepreneurs struggle ...
-
Article dans une revue avec comité de lectureGRAEFF, Eliot; MARANZANA, Nicolas; AOUSSAT, Améziane (American Society of Mechanical Engineers, 2021)Biomimetic practice requires a diverse set of knowledge from both biology and engineering. Several researchers have been supporting the integration of biologists within biomimetic design teams in order to meet those ...
-
Article dans une revue avec comité de lectureEngineering design, as the science framing the practice of design through the elaboration of tools and processes, is constantly evolving towards new innovative strategies. To thrive in their extremely competitive environment, ...
-
Article dans une revue avec comité de lectureYOUSNADJ, Djamel; JOUANNE, Guillaume; BOUCHARD, Carole; MARANZANA, Nicolas; SEGONDS, Frederic; AOUSSAT, Améziane (Springer, 2014)Nowadays, the environment becomes a major issue in our society. It gives rise to regu-lations, market demand and stakeholder's pressure which are concerning companies. These latter have to reduce the negative impact of ...
-
Article dans une revue avec comité de lectureFacing current biomimetics impediments, recent studies have supported the integration within biomimetic teams of a new actor having biological knowledge and know-how. This actor is referred to as the “biomimetician” in ...